23-epi-26-Deoxyactein Inhibitor

Solid. Powder

98.00%

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

660.83

<1mg/ml refers to the product slightly soluble or insoluble

C37H56O10

[H][C@@]12O[C@]1(C)CO[C@]21C[C@@H](C)[C@H]2[C@]([H])(C[C@@]3(C)[C@]4([H])CC[C@]5([H])[C@]6(CC46C[C@H](OC(C)=O)[C@]23C)CC[C@@H](O[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)C5(C)C)O1

264624-38-6

CDK
NOS
NO Synthase

Black cohosh rhizomes were extracted with methanol/water and fractionated by solvent-solvent partitioning to yield three fractions: hexane, ethyl acetate and water. The ethyl acetate fraction displayed the highest potency in two cell-based assays, growth inhibition and cell cycle analysis. This fraction inhibited growth of both the ER+ MCF7 and ER-MDA-MB-453 human breast cancer cell lines with IC50 values of about 20 and 10 micro g/ml, respectively. It also induced cell cycle arrest at G1 when tested at 30 micro g/ml and at G2/M at 60 micro g/ml in MCF7 cells. This suggests that the extract contains a mixture of components with the more active (or more abundant) causing G1 arrest and the less active causing G2/M arrest. We then examined specific components in this extract. The triterpene glycoside fraction obtained by polyamide column chromatography, and the specific triterpene glycosides actein, 23-epi-26-Deoxyactein and cimiracemoside A, inhibited growth of the MCF7 human breast cancer cells and induced cell cycle arrest at G1[1]

Cell Cycle/Checkpoint; CDK; Immunology/Inflammation; Immunology/Inflammation